Document is current

Article History

Received: 12 March 2022

Accepted: 23 March 2022

First Online: 6 April 2022

Declarations

:

: G.C. has received fees for consulting and/or received travel funds from the following companies, which are involved with lipodystrophy: Aegerion/Amryt Pharmaceuticals. S.M. received travel funds from the following company, which is involved with lipodystrophy: Amryt Pharmaceuticals. C.P. received travel funds from the following company, which is involved with lipodystrophy: Amryt Pharmaceuticals. F.S. has worked as a consultant, participated in studies, and/or received travel funds from the following companies, which are involved with lipodystrophy and/or diabetes: AstraZeneca, Aegerion/Amryt, Novo Nordisk.

: This study was exempt from ethical approval procedures being a case report study that describes the clinical course and outcome of two patients who were referred to our outpatient clinic. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.

: All authors have read and agreed to the published article.

: This article does not contain any studies with animals performed by any of the authors.